Abstract
Overview
Introduction
Although Europe is leading the way, the biosimilar industry is very much in
its infancy, with the perception of key decision makers critical to the
initial rate of uptake. The opinion of key stakeholders, and the influence
they wield, will therefore inform the strategy of both the branded and
biosimilar contingents, in what is likely to become a battle to gain trust.
Scope
An overview of the key drivers and resistors to biosimilar use. An outline of
the key stakeholders in Europe and the US, and relative influence they have.
An insight into the opinion of payers, physicians and hospital pharmacists,
regarding biosimilar use. An understanding of how the industry will develop,
and the strategies to be employed by the pro and anti biosimilar factions.
Highlights
Biologics use is set to grow, at a rate that far outstrips that of small
molecule drugs. The considerably greater cost of biologics will therefore
combine with increased utilization to put payers under pressure to promote
biosimilar use.
Due to the complexity of biologic drugs, there are greater concerns regarding
biosimilar safety and efficacy compared with standard generics, which are
likely to only be alleviated following time on the market. Consequently,
initial uptake will be greatly influenced by the perceptions of key
stakeholders.
The opinion of physicians is considered important by both branded and
biosimilar companies, and in Europe this group currently holds the most power.
Although motivated to promote generics, payers and pharmacists to an extent,
often defer to physicians in Europe, although there is evidence this is not
the case in the US.
Reasons to Purchase
- Understand which drugs are subject to biosimilar erosion in Europe now,
and going forward.
- Understand who the key stakeholders are and the influence they have on
biosimilar uptake.
- Gain an insight into how the biosimilar industry will develop, and the
strategies companies will employ to promote or resist uptake.
| 
View Cart
